# Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

> **NCT00516464** · PHASE3 · UNKNOWN · sponsor: **Retina Associates, Kansas City** · enrollment: 40 (estimated)

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Lucentis (ranibizumab)

## Key facts

- **NCT ID:** NCT00516464
- **Lead sponsor:** Retina Associates, Kansas City
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** —
- **Final completion:** 2008-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2007-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516464, "Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00516464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*